Editor's ESMO 2016 roundup
24 Oct 2016
Editor's ESMO 2016 roundup
Abiraterone in patients with recurrent epithelial ovarian cancer
Fatigue in men with castration resistant prostate cancer treated with enzalutamide
PDL-1 assay concordance
TRAIL induced apoptosis for cancer stem cells
Who should receive combination therapy for ER positive breast cancer?
ESMO 2016 conference highlights
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody:
Left versus right sided GI tumour response in the CRYSTAL trial
Looking for new pathways in colorectal cancer
Highlights of ESMO 2016
Advances for NSCLC in review